Strengthening the Product Portfolio with Differentiated Administration Devices

Celltrion Pharm announced on July 1 that it has launched 'Omriclopen Injection 150mg' (active ingredient: omalizumab), a treatment for allergic diseases, in Korea.


Celltrion Pharm Launches 150mg Omriclo AI Formulation in Korea View original image

With this launch, Celltrion Pharm has strengthened its product portfolio by adding an auto-injector (AI) type device to the existing Omriclo line-up, which had previously focused on pre-filled syringes (PFS).


Omriclo is a treatment for allergic asthma and chronic idiopathic urticaria. According to the company, the newly released AI formulation offers a differentiated option from currently marketed omalizumab originator products in Korea, providing a new choice for patients and medical professionals who require self-injectable administration.


The price of Omriclopen Injection 150mg has been set at 173,404 won, the same as the existing Omriclo 150mg PFS. With no price difference between the PFS and AI formulations for the same dosage, healthcare professionals can choose and prescribe the formulation according to patient condition, treatment plan, and administration environment without price constraints.


Previously, Celltrion Pharm supplied Omriclo 75mg and 150mg PFS, and in April expanded its product range to include a 300mg PFS for high dosage needs. The launch of Omriclopen Injection 150mg further expands choices in administration devices, in addition to product range by dosage, reflecting demand from the Korean treatment field, according to the company.


Celltrion Pharm plans to continuously enhance the competitiveness of Omriclo products by considering patient-specific administration environments and the prescribing needs of healthcare professionals.



A representative from Celltrion Pharm said, "With the launch of Omriclopen Injection 150mg, we are now able to supply both PFS and AI formulations in Korea," and added, "We will continue to reflect the needs of patients and healthcare professionals to contribute to improving the treatment environment for allergic diseases in Korea."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing